Standalone and consolidated Q1 FY27 results show year-over-year growth in revenue and net profit, with consolidated net profit rising to Rs 1,799.63 million. Regulatory risks persist due to a USFDA warning, but corrective actions are underway.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.